GlassScriptPhysician profile
Norberto Tuason
NPI 1841338555
$11,198.69
in general payments reported to CMS, 2019-2025
29 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $12.68 · 2021: $735 · 2022: $4,189 · 2023: $3,143 · 2024: $595 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,719 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,718.93 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,583.22 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $967.43 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $946.12 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $903.00 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $825.54 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $805.45 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $788.27 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $595.48 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $558.63 | 2022-2023 | Rexulti, Brintellix |
| Neurocrine Biosciences, INC. | $511.16 | 2019-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $381.85 | 2023-2025 | Qelbree, Qelbree |
| Indivior INC. | $381.65 | 2021-2023 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $313.94 | 2021-2023 | Trintellix |
| Corium, LLC | $263.47 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $236.65 | 2025 | Cobenfy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $235.39 | 2022-2025 | Auvelity |
| Noven Therapeutics, LLC | $213.91 | 2021-2023 | Secuado |
| Allergan, INC. | $197.08 | 2019-2020 | |
| Biogen, INC. | $120.78 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $80.33 | 2021-2023 | Belsomra |
| Sumitomo Pharma America, INC. | $64.85 | 2023 | Latuda |
| Avanir Pharmaceuticals, INC. | $43.51 | 2022 | |
| Ironshore Pharmaceuticals INC. | $40.27 | 2023 | Jornay Pm |
| Eisai INC. | $29.52 | 2021 | |
| Bausch Health US, LLC | $26.55 | 2021 | |
| Noven Pharmaceuticals, INC. | $22.81 | 2022 | |
| Neuronetics, INC. | $22.48 | 2022 | |
| Luye Pharma (USA) LTD. | $20.12 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $19.23 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norberto Tuason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.